hydrogen sulfide has been researched along with Cardiac Failure in 36 studies
Hydrogen Sulfide: A flammable, poisonous gas with a characteristic odor of rotten eggs. It is used in the manufacture of chemicals, in metallurgy, and as an analytical reagent. (From Merck Index, 11th ed)
hydrogen sulfide : A sulfur hydride consisting of a single sulfur atom bonded to two hydrogen atoms. A highly poisonous, flammable gas with a characteristic odour of rotten eggs, it is often produced by bacterial decomposition of organic matter in the absence of oxygen.
thiol : An organosulfur compound in which a thiol group, -SH, is attached to a carbon atom of any aliphatic or aromatic moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although HHcy causes heart failure, interestingly, it is becoming very clear that Hcy can generate hydrogen sulfide (H2S), if the enzymes cystathionine beta-synthase (CBS) and cystathionine gamma-lyase (CGL) are present." | 8.85 | Homocysteine, hydrogen sulfide (H2S) and NMDA-receptor in heart failure. ( Mishra, PK; Tyagi, N; Tyagi, SC, 2009) |
| "Hydrogen sulfide is a critical endogenous signaling molecule that exerts protective effects in the setting of heart failure." | 8.31 | Hydrogen Sulfide Modulates Endothelial-Mesenchymal Transition in Heart Failure. ( Beck, KF; Elrod, JW; Goodchild, TT; Katsouda, A; LaPenna, KB; Lefer, DJ; Li, Z; Papapetropoulos, A; Pfeilschifter, J; Sharp, TE; Xia, H; Xian, M; Xu, S, 2023) |
| "The aim of the present study was to explore whether hydrogen sulfide (H2S) protects against ischemic heart failure (HF) by inhibiting the necroptosis pathway." | 8.12 | Hydrogen sulfide protects against ischemic heart failure by inhibiting RIP1/RIP3/MLKL-mediated necroptosis. ( Chang, L; Dai, J; Gong, J; Lu, H; Luo, Y; Ma, F; Zhu, Y, 2022) |
| " The goal of the present study was to determine the therapeutic potential of a stable, long-acting H2S donor, diallyl trisulfide, in a model of pressure-overload heart failure and to assess the effects of chronic H2S therapy on myocardial vascular density and angiogenesis." | 7.79 | Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis. ( Bhushan, S; Bir, SC; Calvert, JW; Kevil, CG; Kondo, K; Lefer, DJ; Murohara, T; Polhemus, D, 2013) |
| "The aim of this study was to determine whether thioredoxin 1 (Trx1) mediates the cardioprotective effects of hydrogen sulfide (H2S) in a model of ischemic-induced heart failure (HF)." | 7.79 | Thioredoxin 1 is essential for sodium sulfide-mediated cardioprotection in the setting of heart failure. ( Calvert, JW; Lambert, JP; Molkentin, JD; Nicholson, CK; Sadoshima, J, 2013) |
| " A phase I clinical trial of a novel H2 S prodrug (SG1002) was designed to assess safety and changes in H2 S and NO bioavailability in healthy and HF subjects." | 6.80 | A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients. ( Giordano, T; Gojon, G; Krum, H; Li, Z; Pattillo, CB; Polhemus, DJ, 2015) |
| "Hydrogen sulfide (H(2)S) is an endogenous signaling molecule with potent cytoprotective effects." | 5.36 | Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. ( Calvert, JW; Elrod, JW; Elston, M; Gundewar, S; Jha, S; Lefer, DJ; Nicholson, CK; Ramachandran, A, 2010) |
| "Sodium thiosulfate (STS) has been shown to be an antioxidant and calcium solubilizer, but the possible role of STS in dysfunctional ventricles remains unknown." | 5.35 | Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation. ( Hayden, MR; Hughes, WM; Kumar, M; Metreveli, N; Moshal, KS; Sen, U; Tyagi, N; Tyagi, SC; Vacek, TP, 2008) |
| " Although HHcy causes heart failure, interestingly, it is becoming very clear that Hcy can generate hydrogen sulfide (H2S), if the enzymes cystathionine beta-synthase (CBS) and cystathionine gamma-lyase (CGL) are present." | 4.85 | Homocysteine, hydrogen sulfide (H2S) and NMDA-receptor in heart failure. ( Mishra, PK; Tyagi, N; Tyagi, SC, 2009) |
| "Hydrogen sulfide is a critical endogenous signaling molecule that exerts protective effects in the setting of heart failure." | 4.31 | Hydrogen Sulfide Modulates Endothelial-Mesenchymal Transition in Heart Failure. ( Beck, KF; Elrod, JW; Goodchild, TT; Katsouda, A; LaPenna, KB; Lefer, DJ; Li, Z; Papapetropoulos, A; Pfeilschifter, J; Sharp, TE; Xia, H; Xian, M; Xu, S, 2023) |
| "The aim of the present study was to explore whether hydrogen sulfide (H2S) protects against ischemic heart failure (HF) by inhibiting the necroptosis pathway." | 4.12 | Hydrogen sulfide protects against ischemic heart failure by inhibiting RIP1/RIP3/MLKL-mediated necroptosis. ( Chang, L; Dai, J; Gong, J; Lu, H; Luo, Y; Ma, F; Zhu, Y, 2022) |
| "Bioavailability of nitric oxide (NO) and hydrogen sulfide (H2S) is reduced in heart failure (HF)." | 3.83 | Nitrite Therapy Ameliorates Myocardial Dysfunction via H2S and Nuclear Factor-Erythroid 2-Related Factor 2 (Nrf2)-Dependent Signaling in Chronic Heart Failure. ( Bhushan, S; Bradley, JM; Donnarumma, E; Donnelly, EL; Islam, KN; Lefer, DJ; Otsuka, H, 2016) |
| " The goal of the present study was to determine the therapeutic potential of a stable, long-acting H2S donor, diallyl trisulfide, in a model of pressure-overload heart failure and to assess the effects of chronic H2S therapy on myocardial vascular density and angiogenesis." | 3.79 | Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis. ( Bhushan, S; Bir, SC; Calvert, JW; Kevil, CG; Kondo, K; Lefer, DJ; Murohara, T; Polhemus, D, 2013) |
| "The aim of this study was to determine whether thioredoxin 1 (Trx1) mediates the cardioprotective effects of hydrogen sulfide (H2S) in a model of ischemic-induced heart failure (HF)." | 3.79 | Thioredoxin 1 is essential for sodium sulfide-mediated cardioprotection in the setting of heart failure. ( Calvert, JW; Lambert, JP; Molkentin, JD; Nicholson, CK; Sadoshima, J, 2013) |
| " Although in chronic heart failure (CHF) there is robust increase in ROS, RNS, and MMP activation, recent data suggest that hydrogen sulfide (H(2)S, a strong antioxidant gas) is cardioprotective." | 3.76 | H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure. ( Givvimani, S; Mishra, PK; Sen, U; Tyagi, N; Tyagi, SC, 2010) |
| " A phase I clinical trial of a novel H2 S prodrug (SG1002) was designed to assess safety and changes in H2 S and NO bioavailability in healthy and HF subjects." | 2.80 | A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients. ( Giordano, T; Gojon, G; Krum, H; Li, Z; Pattillo, CB; Polhemus, DJ, 2015) |
| "Hydrogen sulfide (H2S) was identified as the third gasotransmitter in 1996 following the discoveries of the biological importance of nitric oxide and carbon monoxide." | 2.55 | Protective Actions of H2S in Acute Myocardial Infarction and Heart Failure. ( Donnarumma, E; Lefer, DJ; Trivedi, RK, 2017) |
| "Cardiac hypertrophy is a critical component of phenotype in the failing heart." | 1.46 | Protective effect of hydrogen sulphide against myocardial hypertrophy in mice. ( Chen, G; Hu, L; Jiang, R; Lin, C; Ping, J; Shan, J; Shao, M; Tian, H; Wang, L; Zhuo, C, 2017) |
| "He rapidly developed cardiorespiratory failure with electrocardiographic, echocardiographic and laboratory findings of myocardial involvement." | 1.40 | [Sewer gas induced myocardial toxicity]. ( Antonelli, D; Rosner, E; Sabanchiev, A; Turgeman, Y, 2014) |
| "Hydrogen sulfide (H(2)S) is an endogenous signaling molecule with potent cytoprotective effects." | 1.36 | Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. ( Calvert, JW; Elrod, JW; Elston, M; Gundewar, S; Jha, S; Lefer, DJ; Nicholson, CK; Ramachandran, A, 2010) |
| "Sodium thiosulfate (STS) has been shown to be an antioxidant and calcium solubilizer, but the possible role of STS in dysfunctional ventricles remains unknown." | 1.35 | Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation. ( Hayden, MR; Hughes, WM; Kumar, M; Metreveli, N; Moshal, KS; Sen, U; Tyagi, N; Tyagi, SC; Vacek, TP, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (8.33) | 29.6817 |
| 2010's | 26 (72.22) | 24.3611 |
| 2020's | 7 (19.44) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, L | 1 |
| Gong, W | 1 |
| Zhang, S | 1 |
| Shen, J | 1 |
| Wang, Y | 1 |
| Chen, Y | 1 |
| Meng, G | 1 |
| Liu, Q | 1 |
| Ji, G | 1 |
| Chu, Y | 1 |
| Hao, T | 1 |
| Qian, M | 1 |
| Zhao, Q | 1 |
| Li, Z | 3 |
| Xia, H | 2 |
| Sharp, TE | 2 |
| LaPenna, KB | 2 |
| Elrod, JW | 3 |
| Casin, KM | 1 |
| Liu, K | 1 |
| Calvert, JW | 7 |
| Chau, VQ | 1 |
| Salloum, FN | 1 |
| Xu, S | 2 |
| Xian, M | 2 |
| Nagahara, N | 1 |
| Goodchild, TT | 2 |
| Lefer, DJ | 8 |
| Kolluru, GK | 1 |
| Shackelford, RE | 1 |
| Shen, X | 1 |
| Dominic, P | 1 |
| Kevil, CG | 2 |
| Ma, F | 2 |
| Zhu, Y | 1 |
| Chang, L | 2 |
| Gong, J | 1 |
| Luo, Y | 1 |
| Dai, J | 1 |
| Lu, H | 1 |
| Katsouda, A | 1 |
| Pfeilschifter, J | 1 |
| Beck, KF | 1 |
| Papapetropoulos, A | 1 |
| Huang, S | 1 |
| Chen, X | 1 |
| Pan, J | 1 |
| Zhang, H | 2 |
| Ke, J | 1 |
| Gao, L | 1 |
| Yu Chang, AC | 1 |
| Zhang, J | 1 |
| Tran, BH | 2 |
| Yu, Y | 1 |
| Tan, B | 1 |
| Jia, W | 1 |
| Xiong, Y | 1 |
| Dai, T | 1 |
| Zhong, R | 1 |
| Zhang, W | 1 |
| Le, VM | 1 |
| Rose, P | 1 |
| Wang, Z | 1 |
| Mao, Y | 1 |
| Zhu, YZ | 5 |
| Donnarumma, E | 2 |
| Trivedi, RK | 1 |
| Shao, M | 1 |
| Zhuo, C | 1 |
| Jiang, R | 1 |
| Chen, G | 1 |
| Shan, J | 1 |
| Ping, J | 1 |
| Tian, H | 1 |
| Wang, L | 1 |
| Lin, C | 1 |
| Hu, L | 1 |
| Shimizu, Y | 2 |
| Polavarapu, R | 1 |
| Eskla, KL | 1 |
| Nicholson, CK | 5 |
| Koczor, CA | 1 |
| Wang, R | 2 |
| Lewis, W | 1 |
| Shiva, S | 1 |
| Abdelmonem, M | 1 |
| Shahin, NN | 1 |
| Rashed, LA | 1 |
| Amin, HAA | 1 |
| Shamaa, AA | 1 |
| Shaheen, AA | 1 |
| Del Rio, R | 2 |
| Marcus, NJ | 2 |
| Schultz, HD | 2 |
| Liu, YH | 1 |
| Lu, M | 1 |
| Xie, ZZ | 1 |
| Hua, F | 1 |
| Xie, L | 1 |
| Gao, JH | 1 |
| Koh, YH | 1 |
| Bian, JS | 1 |
| Kitajima, N | 1 |
| Nishida, M | 1 |
| Polhemus, D | 1 |
| Kondo, K | 2 |
| Bhushan, S | 3 |
| Bir, SC | 1 |
| Murohara, T | 3 |
| Huang, C | 1 |
| Kan, J | 1 |
| Liu, X | 1 |
| Zou, Y | 1 |
| Wang, S | 1 |
| Zhao, Z | 1 |
| Deng, P | 1 |
| Antonelli, D | 1 |
| Sabanchiev, A | 1 |
| Rosner, E | 1 |
| Turgeman, Y | 1 |
| Polhemus, DJ | 1 |
| Pattillo, CB | 1 |
| Gojon, G | 4 |
| Giordano, T | 1 |
| Krum, H | 1 |
| Shen, Y | 1 |
| Shen, Z | 1 |
| Luo, S | 1 |
| Guo, W | 2 |
| Wen, YD | 1 |
| Lambert, JP | 2 |
| Barr, LA | 1 |
| Kuek, N | 1 |
| Herszenhaut, D | 1 |
| Tan, L | 1 |
| Hansen, JM | 1 |
| Husain, A | 1 |
| Naqvi, N | 1 |
| Bradley, JM | 1 |
| Otsuka, H | 2 |
| Donnelly, EL | 1 |
| Islam, KN | 1 |
| Sen, U | 3 |
| Vacek, TP | 1 |
| Hughes, WM | 1 |
| Kumar, M | 1 |
| Moshal, KS | 1 |
| Tyagi, N | 4 |
| Metreveli, N | 1 |
| Hayden, MR | 1 |
| Tyagi, SC | 4 |
| Amino, M | 1 |
| Yoshioka, K | 1 |
| Suzuki, Y | 1 |
| Uemura, S | 1 |
| Sakurai, K | 1 |
| Fukushima, T | 1 |
| Morita, S | 1 |
| Nakagawa, Y | 1 |
| Yamamoto, I | 1 |
| Kodama, I | 1 |
| Inokuchi, S | 1 |
| Tanabe, T | 1 |
| Mishra, PK | 2 |
| Givvimani, S | 2 |
| Chaari, A | 1 |
| Bahloul, M | 1 |
| Chelly, H | 1 |
| Sahnoun, M | 1 |
| Bouaziz, M | 1 |
| Wang, X | 1 |
| Wang, Q | 1 |
| Elston, M | 1 |
| Gundewar, S | 1 |
| Jha, S | 1 |
| Ramachandran, A | 1 |
| Munjal, C | 1 |
| Gargoum, R | 1 |
| Vacek, JC | 1 |
| Ding, Y | 1 |
| Gan, XB | 1 |
| Liu, TY | 1 |
| Xiong, XQ | 1 |
| Chen, WW | 1 |
| Zhou, YB | 1 |
| Zhu, GQ | 1 |
| Molkentin, JD | 1 |
| Sadoshima, J | 1 |
| King, AL | 1 |
| Prabhu, SD | 1 |
| Hamid, T | 1 |
| Koenig, S | 1 |
| Predmore, BL | 1 |
| Karusula, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Short-Term Endogenous Hydrogen Sulfide Upregulation For Vein Graft Disease[NCT05457881] | 226 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | |||
| A Dose Escalation Study to Assess the Safety and Ability of SG1002 to Overcome Circulating Deficits in Hydrogen Sulfide Found in Heart Failure Patients[NCT01989208] | 16 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
At the start of each dose, blood samples will be obtained and circulating hydrogen sulfide levels will be assessed over a 24 hour period to determine whether SG1002 can overcome the deficits reported in heart failure patients. Peak hydrogen sulfide levels were measured during the first 4 hours post-administration when maximum concentrations of hydrogen sulfide were reached. (NCT01989208)
Timeframe: 24 hours
| Intervention | uM (Mean) |
|---|---|
| Baseline | 0.37 |
| 200 mg SG1002 | 0.44 |
| 400 mg SG002 | 0.50 |
| 800 mg SG1002 | 0.51 |
BNP levels were measured for the each subject prior to treatment and after 7 days on each treatment dose, thus representing a change in BNP over the 21 day treatment period. Increased BNP levels are associated with worsening heart failure. (NCT01989208)
Timeframe: 7 days at each dose.
| Intervention | pg/ml (Mean) |
|---|---|
| Sugar Capsule: Day 0 | 85.0 |
| Sugar Capsules: Day 7 | 123.0 |
| Sugar Capsules: Day 14 | 156.5 |
| Sugar Capsules: Day 21 | 149.5 |
| SG1002: Day 0 | 77.5 |
| SG1002: Day 7 | 69.8 |
| SG1002: Day 14 | 79.0 |
| SG1002: Day 21 | 72.0 |
The number of subjects reporting Treatment Emergent Adverse Events at any time during the study period. (NCT01989208)
Timeframe: Following 7 days of treatment at each of three doses
| Intervention | participants (Number) | |
|---|---|---|
| Subjects with Treatment Adverse Events | Subjects with no Treatment Emergent Adverse Events | |
| SG1002 | 3 | 9 |
| Sugar Capsule | 2 | 2 |
8 reviews available for hydrogen sulfide and Cardiac Failure
| Article | Year |
|---|---|
Sulfide regulation of cardiovascular function in health and disease.
Topics: Heart; Heart Failure; Humans; Hydrogen Sulfide; Myocardial Infarction; Sulfides | 2023 |
Protective Actions of H2S in Acute Myocardial Infarction and Heart Failure.
Topics: Acute Disease; Animals; Cardiotonic Agents; Heart Failure; Humans; Hydrogen Sulfide; Mitochondria; M | 2017 |
[Chemical biology of hydrogen sulfide].
Topics: Biological Factors; Cardiotonic Agents; Cystathionine beta-Synthase; Cystathionine gamma-Lyase; Drug | 2013 |
[Research update of copeptin and hydrogen sulfide in the pathogenesis of chronic heart failure].
Topics: Glycopeptides; Heart Failure; Humans; Hydrogen Sulfide | 2014 |
The Cardioprotective Effects of Hydrogen Sulfide in Heart Diseases: From Molecular Mechanisms to Therapeutic Potential.
Topics: Animals; Heart Diseases; Heart Failure; Hydrogen Sulfide; Mitochondria; Nitric Oxide; Protective Age | 2015 |
The Pharmacological Effects of S-Propargyl-Cysteine, a Novel Endogenous H2S-Producing Compound.
Topics: Animals; Chemistry, Pharmaceutical; Cysteine; Heart Failure; Humans; Hydrogen Sulfide; Myocardial Is | 2015 |
Homocysteine, hydrogen sulfide (H2S) and NMDA-receptor in heart failure.
Topics: Animals; Gene Deletion; Heart Failure; Homocysteine; Humans; Hydrogen Sulfide; Myocardial Contractio | 2009 |
Role of neurotransmitter gases in the control of the carotid body in heart failure.
Topics: Animals; Carbon Monoxide; Carotid Body; Gases; Heart Failure; Humans; Hydrogen Sulfide; Neurotransmi | 2012 |
1 trial available for hydrogen sulfide and Cardiac Failure
| Article | Year |
|---|---|
A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Biomarkers; Glutathione; Heart Failure; | 2015 |
27 other studies available for hydrogen sulfide and Cardiac Failure
| Article | Year |
|---|---|
Hydrogen Sulfide Attenuates Angiotensin II-Induced Cardiac Fibroblast Proliferation and Transverse Aortic Constriction-Induced Myocardial Fibrosis through Oxidative Stress Inhibition via Sirtuin 3.
Topics: Actins; Angiotensin II; Animals; Cell Proliferation; Collagen; Dynamins; Fibroblasts; Heart Failure; | 2021 |
Enzyme-responsive hybrid prodrug of nitric oxide and hydrogen sulfide for heart failure therapy.
Topics: Cardiotonic Agents; Diuretics; Enzyme Inhibitors; Heart Failure; Humans; Hydrogen Sulfide; Myocardia | 2022 |
Mitochondrial H
Topics: Adenosine Triphosphate; Amino Acids, Branched-Chain; Animals; Heart Failure; Humans; Hydrogen Sulfid | 2022 |
Hydrogen sulfide protects against ischemic heart failure by inhibiting RIP1/RIP3/MLKL-mediated necroptosis.
Topics: Animals; Heart Failure; Hydrogen Sulfide; Mice; Myocardial Infarction; Necroptosis; Protein Kinases | 2022 |
Hydrogen Sulfide Modulates Endothelial-Mesenchymal Transition in Heart Failure.
Topics: Animals; Endothelial Cells; Endothelium, Vascular; Fibrosis; Heart Failure; Hydrogen Sulfide; Mice; | 2023 |
Hydrogen sulfide alleviates heart failure with preserved ejection fraction in mice by targeting mitochondrial abnormalities via PGC-1α.
Topics: Animals; Cystathionine gamma-Lyase; Heart Failure; Hydrogen Sulfide; Male; Mice; Mice, Inbred C57BL; | 2023 |
A Novel Liposomal S-Propargyl-Cysteine: A Sustained Release of Hydrogen Sulfide Reducing Myocardial Fibrosis via TGF-β1/Smad Pathway.
Topics: Animals; Antioxidants; Cardiotonic Agents; Cystathionine gamma-Lyase; Cysteine; Disease Models, Anim | 2019 |
Protective effect of hydrogen sulphide against myocardial hypertrophy in mice.
Topics: Animals; Aorta; Cardiomegaly; Cells, Cultured; Disease Models, Animal; Echocardiography; Heart Failu | 2017 |
Hydrogen sulfide regulates cardiac mitochondrial biogenesis via the activation of AMPK.
Topics: AMP-Activated Protein Kinases; Animals; Cell Nucleus; DNA, Mitochondrial; Enzyme Activation; Heart F | 2018 |
Hydrogen sulfide enhances the effectiveness of mesenchymal stem cell therapy in rats with heart failure: In vitro preconditioning versus in vivo co-delivery.
Topics: Animals; Combined Modality Therapy; Heart Failure; Hydrogen Sulfide; Ischemic Preconditioning, Myoca | 2019 |
Inhibition of hydrogen sulfide restores normal breathing stability and improves autonomic control during experimental heart failure.
Topics: Alkynes; Analysis of Variance; Animals; Autonomic Nervous System; Blood Pressure; Carotid Body; Chem | 2013 |
Hydrogen sulfide prevents heart failure development via inhibition of renin release from mast cells in isoproterenol-treated rats.
Topics: Animals; Cardiotonic Agents; Cell Line; Collagen; Epoxide Hydrolases; Female; Heart Failure; Heart V | 2014 |
Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis.
Topics: Allyl Compounds; Angiostatins; Animals; Disease Models, Animal; Fibrosis; Heart Failure; Hydrogen Su | 2013 |
Cardioprotective effects of a novel hydrogen sulfide agent-controlled release formulation of S-propargyl-cysteine on heart failure rats and molecular mechanisms.
Topics: Animals; Apoptosis; Cardiotonic Agents; Cysteine; Delayed-Action Preparations; Disease Models, Anima | 2013 |
[Sewer gas induced myocardial toxicity].
Topics: Echocardiography; Electrocardiography; Heart Failure; Humans; Hydrogen Sulfide; Male; Myocardium; Oc | 2014 |
Sodium Sulfide Attenuates Ischemic-Induced Heart Failure by Enhancing Proteasomal Function in an Nrf2-Dependent Manner.
Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Endoplasmic Reticulum Stress; Heart Failure; | 2016 |
Nitrite Therapy Ameliorates Myocardial Dysfunction via H2S and Nuclear Factor-Erythroid 2-Related Factor 2 (Nrf2)-Dependent Signaling in Chronic Heart Failure.
Topics: Animals; Antioxidants; Cardiotonic Agents; Coronary Occlusion; Heart Failure; Hydrogen Sulfide; Male | 2016 |
Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation.
Topics: Adenylyl Cyclases; Animals; Aorta; Arteriovenous Fistula; Cardiotonic Agents; Chronic Disease; Colla | 2008 |
Improvement in a patient suffering from cardiac injury due to severe hydrogen sulfide poisoning: a long-term examination of the process of recovery of heart failure by performing nuclear medicine study.
Topics: 3-Iodobenzylguanidine; Adult; Echocardiography; Electrocardiography; Fatty Acids; Heart Failure; Hum | 2009 |
H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure.
Topics: ADAM Proteins; ADAM12 Protein; Animals; Antioxidants; Apoptosis; Chronic Disease; Disease Models, An | 2010 |
[Neurological and heart failure following an accidental intoxication by hydrogen sulphide: a case report].
Topics: Accidental Falls; Adult; Coma; Coronary Angiography; Heart Failure; Humans; Hydrogen Sulfide; Male; | 2010 |
Hydrogen sulfide attenuates cardiac dysfunction in a rat model of heart failure: a mechanism through cardiac mitochondrial protection.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blood Pressure; Cardiotonic Agents; Caspase 3; Cytoc | 2011 |
Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice.
Topics: Animals; Body Weight; Cardiomegaly; Cystathionine gamma-Lyase; Gene Expression Regulation, Enzymolog | 2010 |
Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure.
Topics: Analysis of Variance; Animals; Blotting, Western; Cardiomegaly; Disease Progression; Echocardiograph | 2011 |
Hydrogen sulfide in paraventricular nucleus enhances sympathetic activity and cardiac sympathetic afferent reflex in chronic heart failure rats.
Topics: Analysis of Variance; Animals; Arterial Pressure; Heart Failure; Hydrogen Sulfide; Paraventricular H | 2012 |
Thioredoxin 1 is essential for sodium sulfide-mediated cardioprotection in the setting of heart failure.
Topics: Active Transport, Cell Nucleus; Animals; Cardiotonic Agents; Disease Models, Animal; Genes, Reporter | 2013 |
H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase.
Topics: Animals; Cardiotonic Agents; Cystathionine gamma-Lyase; Heart Failure; Hydrogen Sulfide; Male; Mice; | 2013 |